ArticleScientific reports2025
Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute subjective experiences induced by psychedelics have been identified as important mediators of therapeutic outcomes in many studies. Mystical experiences specifically, have been correlated with a range of therapeutic outcomes including reductions in symptoms of depression, anxiety and addiction. This paper assesses acute subjective experiences induced by an encapsulated DMT-harmala alkaloid product and associations with persisting psychological effects. Botanically derived purified and partially purified formulations containing precise levels of DMT and three harmala alkaloids were administered in 17 dosing sessions to 9 healthy volunteers, with acute subjective experiences data collected via three psychometric instruments (MEQ-30, 5D-ASC, and newly adapted SIME). Pearson's correlations and linear mixed models investigated dose-response relationships and associations with persisting psychological effects. Further analysis compared acute subjective experience scores in this study to ayahuasca drinkers in various naturalistic contexts. Strong, significant positive correlations were identified between total dose and MEQ and SIME scores. The purified DMT-harmala formulation reliably elicited strong acute subjective experiences, with scores exceeding those reported in most previous studies. These experiences were robustly associated with a range of beneficial persisting psychological effects. Findings suggest that this formulation warrants further investigation in controlled clinical trials with relevant patient populations to assess therapeutic potential and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.